The Federal Trade Commission (FTC) sued Golden Sunrise Nutraceutical for allegedly deceptively advertising its $23,000 COVID-19 treatment plan as “FDA accepted.”
Golden Sunrise Nutraceutical is a company based in Porterville, California. The company sells a variety of dietary supplements and claims that these products provide numerous health benefits including curing serious diseases.
The federal consumer protection watchdog also names Golden Sunrise Nutraceutical’s CEO Huu Tieu and Medical Director Stephen Meis as defendants in the case.
In the lawsuit, the FTC noted that the defendants are marketing their dietary supplements through four plans of care: 1) Primary Plan of Care; 2) Emergency D-Virus of Care; 3) Metabolic Plan of Care, 4) Cancer Plan of Care. They claimed that these treatment plans provide consumers with safe and effective treatment for serious diseases.
In March 2020, Golden Sunrise Nutraceutical started marketing its Emergency D-Virus plan as a treatment for COVID-19.
Allegations against Golden Sunrise Nutraceutical
The FTC alleged that the defendants falsely claimed in its advertisements on billboards, websites, and social media that its herbal supplements ImunStem, Aktiffvate, and AnterFeerons are “uniquely qualified to treat and modify the course of the Coronavirus epidemic in CHINA and other countries.”
